Morrison & Foerster LLP advised Menlo Therapeutics Inc. on its initial public offering of 8,050,000 shares of common stock at a public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,050,000 shares of common stock. Aggregate gross proceeds to the company were approximately $136.9 million before underwriting discounts, commissions, and estimated offering expenses. Menlo is now listed on the NASDAQ Global Select Market (NASDAQ) under the symbol “MNLO”. The offering closed on January 29, 2018.
Based in Redwood City, California, Menlo is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough. MoFo previously advised biotechnology companies Fulgent Genetics and Krystal Biotech, Inc on their IPOs.
The MoFo team advising Menlo was led by Northern Virginia-based corporate partner Stephen Thau and San Francisco-based corporate partner Alfredo Silva.
Jefferies LLC, Piper Jaffray & Co., and Guggenheim Securities, LLC acted as joint book-running managers in connection with the offering.
See the related press release.
Select media coverage: